CASI Pharmaceuticals, Inc (DE)
CASIDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000895051
CASI Pharmaceuticals, Inc (DE) was delisted in 2023; its insiders filed their last Form 4 on Sep 9, 2022; 23 institutions reported holding it in 13F filings for Q4 2022, worth $3.31M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by CASI Pharmaceuticals, Inc (DE) insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for CASI Pharmaceuticals, Inc (DE), current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Zukiwski Alexander A | EVP and Chief Medical Officer | – | Sep 9, 2022 | 0 |
| Huang James | Director | 371,517Indirect | Sep 8, 2022 | 0 |
| He Wei-Wu | Chairman and CEO | 644,553 | Jun 17, 2022 | 0 |
| Shrotriya Rajesh C MD | Director | – | May 26, 2022 | 0 |
| Zhou Quan | Director | – | May 26, 2022 | 0 |
| Salisbury Franklin Cary jr | Director | – | May 26, 2022 | 0 |
| Wu Yue Alexander | Director | – | May 26, 2022 | 0 |
| Zhang Larry | President | – | Jul 26, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2022 (view filing) | Sep 6-8 | 2 days | Huang JamesDirector | PPurchase | +55.6K | $4.13 | +$229.5K | +17.6%371.5K after | 3 lots |
| Sep 2, 2022 (view filing) | Aug 31-Sep 2 | 2 days | Huang JamesDirector | PPurchase | +37.2K | $3.74 | +$139.1K | +13.3%315.9K after | 3 lots |
| Aug 26, 2022 (view filing) | Aug 24-26 | 2 days | Huang JamesDirector | PPurchase | +44.5K | $3.75 | +$167.0K | +19.0%278.7K after | 2 lots |
| Aug 23, 2022 (view filing) | Aug 19-23 | 4 days | Huang JamesDirector | PPurchase | +234.2K | $3.33 | +$779.5K | New position234.2K after | 3 lots |
| Jun 17, 2022 (view filing) | Jun 13-15 | 4 daysLate | He Wei-WuChairman and CEO | PPurchase | +88.2K | $3.09 | +$272.5K | +15.8%644.6K after | 3 lots |
| Nov 19, 2021 (view filing) | Nov 17-18 | 2 days | He Wei-WuChairman and CEO | PPurchase | +400.0K | $0.985 | +$394.0K | +7.8%5.56M after | 2 lots |
| Aug 20, 2021 (view filing) | Aug 18-19 | 2 days | He Wei-WuChairman and CEO | PPurchase | +480.0K | $1.28 | +$613.8K | +10.2%5.16M after | 2 lots |